Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To investigate the effects of anti-vascular endothelial growth factor (VEGF) antibody on the survival ofretinal ganglion cell (RGC)-5 cells differentiated with staurosporine under oxidative stress. Methods: We used real-time polymerase chain reaction and Western blot to confirm the expression of VEGF,VEGF receptor (VEGFR)-1 and VEGFR-2 in RGC-5 cells differentiated with staurosporine for 6 hours. The differentiatedRGC-5 cells were treated with 800 μM hydrogen peroxide (H2O2) for 24 hours to induce oxidativestress. Then, the survival rate of RGC-5 was confirmed by lactate dehydrogenase assay at each concentration(0, 0.01, 0.1, and 1 mg) using bevacizumab as the anti-VEGF antibody. The expression of VEGF, VEGFR-1,and VEGFR-2 was confirmed using real-time polymerase chain reaction. Results: VEGF, VEGFR-1, and VEGFR-2 were all expressed in differentiated RGC-5 cells. When RGC-5 cellswere simultaneously treated with bevacizumab and 800 μM H2O2, survival of RGC-5 decreased with bevacizumabconcentration. VEGF expression in RGC-5 cells increased with increasing concentration of bevacizumab. Similar patterns were observed for VEGFR-1 and VEGFR-2, but the degree of increase was smaller thanthat for VEGF. Conclusions: When bevacizumab was administered to differentiated RGC-5 cells, the cell damage caused byoxidative stress increased. Therefore, given these in vitro study results, caution should be exercised with bevacizumabtreatment.
Abstract
Purpose: To investigate the effects of anti-vascular endothelial growth factor (VEGF) antibody on the survival ofretinal ganglion cell (RGC)-5 cells differentiated with staurosporine under oxidative stress. Methods: We used real-time polymerase chain reaction and Western blot to confirm the expression of VEGF,VEGF receptor (VEGFR)-1 and VEGFR-2 in RGC-5 cells differentiated with staurosporine for 6 hours. The differentiatedRGC-5 cells were treated with 800 μM hydrogen peroxide (H2O2) for 24 hours to induce oxidativestress. Then, the survival rate of RGC-5 was confirmed by lactate dehydrogenase assay at each concentration(0, 0.01, 0.1, and 1 mg) using bevacizumab as the anti-VEGF antibody. The expression of VEGF, VEGFR-1,and VEGFR-2 was confirmed using real-time polymerase chain reaction. Results: VEGF, VEGFR-1, and VEGFR-2 were all expressed in differentiated RGC-5 cells. When RGC-5 cellswere simultaneously treated with bevacizumab and 800 μM H2O2, survival of RGC-5 decreased with bevacizumabconcentration. VEGF expression in RGC-5 cells increased with increasing concentration of bevacizumab. Similar patterns were observed for VEGFR-1 and VEGFR-2, but the degree of increase was smaller thanthat for VEGF. Conclusions: When bevacizumab was administered to differentiated RGC-5 cells, the cell damage caused byoxidative stress increased. Therefore, given these in vitro study results, caution should be exercised with bevacizumabtreatment.
참고문헌 (22)
- Wise GN, "Retinal neovascularization", Trans Am Ophthalmol Soc, 54, pp.729~826 (1956)
- Adamis AP, "Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy", Am J Ophthalmol, 118, pp.445~450 (1994)
- Miller JW, "Vascular endothelial growth factor", vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model, 1994, pp.145, 574~584
- Drobek-Slowik M, "The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD)", Postepy Hig Med Dosw (Online), 61, pp.28~37 (2007)
- Beatty S, "The role of oxidative stress in the pathogenesis of age-related macular degeneration", Surv Ophthalmol, 45, pp.115~134 (2000)
- Esser S, "Vascular endothelial growth factor induces endothelial fenestrations in vitro", J Cell Biol, 140, pp.947~959 (1998)
- Wang Y, "Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice", J Neurosci, 27, pp.304~307 (2007)
- Saint-Geniez M, "Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors", PLoS One, 3, pp.e3554~ (2008)
- Storkebaum E, "VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection", Bioessays, 26, pp.943~954 (2004)
- Aiello LP, "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders", N Engl J Med, 331, pp.1480~1487 (1994)
- Ferrara N, "Targeting VEGF-A to treat cancer and age-related macular degeneration", Annu Rev Med, 58, pp.491~504 (2007)
- Ozaki H, "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization", Am J Pathol, 156, pp.697~707 (2000)
- Gragoudas ES, "Pegaptanib for neovascular age-related macular degeneration", N Engl J Med, 351, pp.2805~2816 (2004)
- van der Reis MI, "A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections", Retina, 31, pp.1449~1469 (2011)
- Foxton RH, "VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma", Am J Pathol, 182, pp.1379~1390 (2013)
- Charles I, "Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cells via mitochondrial signaling pathways", Invest Ophthalmol Vis Sci, 46, pp.1330~1338 (2005)
- Maher P, "The molecular basis of oxidative stress-induced cell death in an immortalized retinal ganglion cell line", Invest Ophthalmol Vis Sci, 46, pp.749~757 (2005)
- 나경두, "배양된 망막신경절세포주에서 허혈전처치와 Protein kinase C의 역할", 대한안과학회지, 49(6), pp.979~986 (2008), 대한안과학회
- Na JH, "Detection of macular ganglion cell loss in preperimetric glaucoma patients with localized retinal nerve fibre defects by spectral-domain optical coherence tomography", Clin Exp Ophthalmol, 41, pp.870~880 (2013)
- Chen SD, "Neuroprotection in glaucoma:present and future", Chin Med J (Engl), 126, pp.1567~1577 (2013)
- Weinreb RN, "Glaucoma neuroprotection: what is it? Why is it needed?", Can J Ophthalmol, 42, pp.396~398 (2007)
- Krishnamoorthy RR, "A forensic path to RGC-5 cell line identification: lessons learned", Invest Ophthalmol Vis Sci, 54, pp.5712~5719 (2013)